Clinical Orthopaedics and Related Research ®

A Publication of The Association of Bone and Joint Surgeons ®

Symposium: Musculoskeletal Tumor Society 2012 Symposium 9 articles


Silver Negative Pressure Dressing With Vacuum-assisted Closure of Massive Pelvic and Extremity Wounds

Herrick J. Siegel MD, Diego F. Herrera MD, Jason Gay CRNFA

Massive soft tissue loss involving the pelvis and extremities from trauma, infections, and tumors remains a challenging and debilitating problem. Although vacuum-assisted closure (VAC) technology is effective in the management of soft tissue loss, the adjunct of a silver dressing in the setting of massive wounds has not been as well tested.

Chick Embryo Extract Demethylates Tumor Suppressor Genes in Osteosarcoma Cells

Xiaodong Mu PhD, Bolat Sultankulov BS, Riddhima Agarwal, Adel Mahjoub, Trevor Schott BS, Nicholas Greco MD, Johnny Huard PhD, Kurt Weiss MD

Epigenetics is the study of changes in gene expression or cellular phenotype caused by mechanisms other than changes in the underlying DNA sequence. It is widely accepted that cancer has genetic and epigenetic origins. The idea of epigenetic reprogramming of cancer cells by an embryonic microenvironment possesses potential interest from the prospect of both basic science and potential therapeutic strategies. Chick embryo extract (CEE) has been used for the successful expansion of many specific stem cells and has demonstrated the ability to facilitate DNA demethylation.

How Long Should We Follow Patients With Soft Tissue Sarcomas?

Chigusa Sawamura MD, MPH, Seiichi Matsumoto MD, PhD, Takashi Shimoji MD, PhD, Atsushi Okawa MD, PhD, Keisuke Ae MD, PhD

Guidelines suggest that followup for low-grade soft tissue sarcomas should be every 3 to 6 months for 2 to 3 years and then annually, and for high-grade sarcomas every 3 to 6 months for 2 to 5 years, then every 6 months for the next 2 years, and then annually. However, there is only very limited evidence to support these strategies.

Loss of SS18-SSX1 Inhibits Viability and Induces Apoptosis in Synovial Sarcoma

Emily E. Carmody Soni MD, Silke Schlottman PhD, Hayriye V. Erkizan PhD, Aykut Uren MD, Jeffrey A. Toretsky MD

Most synovial sarcomas contain a chromosomal translocation t(X;18), which results in the formation of an oncoprotein SS18-SSX critical to the viability of synovial sarcoma.

Radiation Therapy Is Associated With Fewer Recurrences in Mesenchymal Chondrosarcoma

Satoshi Kawaguchi MD, Israel Weiss MD, Patrick P. Lin MD, Winston W. Huh MD, Valerae O. Lewis MD

Mesenchymal chondrosarcoma (MSC) is a rare variant of chondrosarcoma. Because of the rarity of the disease, most studies only contain a small number of patients and thus the prognostic variables and role of adjuvant therapies remain controversial.

Chemotherapy Influences the Pseudocapsule Composition in Soft Tissue Sarcomas

Patrick W. O’Donnell MD, PhD, J. Carlos Manivel MD, Edward Y. Cheng MD, Denis R. Clohisy MD

Soft tissue sarcomas are a heterogeneous group of malignant tumors. Standard treatment for soft tissue sarcoma of the extremity is surgical excision and adjuvant therapy; however, the role of neoadjuvant chemotherapy is controversial.

Frozen Section versus Gross Examination for Bone Marrow Margin Assessment During Sarcoma Resection

Megan E. Anderson MD, Patricia E. Miller MS, Kelsey Nostrand BS, Sara O. Vargas MD

Complete resection is critical for local control of primary bone sarcomas. Intraoperative consultation, including frozen section of bone marrow margins, frequently is used to aid in this goal.

A Dual-center Review of Compressive Osseointegration for Fixation of Massive Endoprosthetics: 2- to 9-year Followup

George T. Calvert MD, Judd E. Cummings MD, Austin J. Bowles MS, Kevin B. Jones MD, L. Daniel Wurtz MD, R. Lor Randall MD

Aseptic failure of massive endoprostheses used in the reconstruction of major skeletal defects remains a major clinical problem. Fixation using compressive osseointegration was developed as an alternative to cemented and traditional press-fit fixation in an effort to decrease aseptic failure rates.